The EU’s medical device regulation

Medical device manufacturers seeking market access to the European Union (EU) will soon face major changes in the EU’s decades-old regulatory framework. The EU’s Medical Device Regulation (MDR) was officially published on 5 May 2017 and came into force on 25 May 2017. The MDR will replace the EU’s current Medical Device Directive (93/42/EEC) and the EU’s Directive on active implantable medical devices (90/385/EEC).

Background

The origins of the MDR date back to 2008, when the EU Commission initiated a public consultation on the Community’s existing requirements covering medical devices. This consultation produced more than 200 comments and proposals for change from a wide variety of stakeholders. As a result, the Commission released in 2012 its plan to restructure the EU’s medical device regulatory framework, along with a regulation that would replace existing directives for medical devices and active implantable medical devices.

The expected changes and their impact

The MDR differs in several important ways from the EU’s current directives for medical devices and active implantable medical devices. Changes in the regulation include expansion of the scope of products covered, more rigorous requirements for clinical evaluation including changes to clinical investigations, mandatory unique device identification (UDI) mechanisms, and increased post-market oversight by EU Notified Bodies.

Specific details on these and other changes, along with their anticipated impact include:

- **Product scope expansion** – The definition of medical devices and active implantable medical devices covered under the MDR is expected to be significantly expanded to include devices that may not have a medical intended purpose, such as coloured contact lenses and cosmetic implant devices and materials. Also for inclusion within the scope of the regulation are devices designed for the purpose of “prediction” of a disease or other health condition.
Reclassification of devices according to risk, contact duration and invasiveness – The MDR will require device manufacturers to review the updated classification rules and update their technical documentation accordingly by considering the fact that class III and implantable devices will have higher clinical requirements and a regular scrutiny process. It is expected that device manufacturers will also be required to collect and retain post-market clinical data as part of the ongoing assessment of potential safety risks. These changes will result in a dramatic increase in the time and resources needed by manufacturers to conduct the required studies and to maintain post-market documentation.

More rigorous clinical evidence for class III and implantable medical devices – Manufacturers will need to conduct clinical investigations in case they do not have sufficient clinical evidence to support the claims done on both safety and performance of a dedicated device.

Systematic clinical evaluation of Class IIa and Class IIb medical devices – Manufacturers will need to re-prepare their clinical evaluations by considering the new wording of the regulation on when an equivalence approach and under which circumstances it is possible to justify not conducting a clinical investigation.

Identification of “qualified person” – Device manufacturers will be required to identify at least one person within their organisation who is ultimately responsible for all aspects of compliance with the requirements of the new MDR. The organisation must document the specific qualifications of this individual relative to the required tasks. Further, qualifications of responsible persons will be subject to review by Notified Bodies to ensure requisite knowledge and skill.

Implementation of unique device identification – The MDR mandates the use of unique device identification (UDI) mechanisms. This requirement is expected to increase the ability of manufacturers and authorities to trace specific devices through the supply chain, and to facilitate the prompt and efficient recall of medical devices that have been found to present a safety risk. To support this effort, the European Databank on Medical Devices (Eudamed) is expected to be expanded to provide more efficient access to information on approved medical devices.

Rigorous post-market oversight – The MDR will grant Notified Bodies increased post-market surveillance authority. Unannounced audits, along with product sample checks and product testing will strengthen the EU’s enforcement regime and help to reduce risks from unsafe devices. Annual safety and performance reporting by device manufacturers will also be required in many cases.

Specifications – The MDR will give the EU Commission or expert panels the authority to publish Common Specifications. These Common Specifications would exist in parallel to the Harmonised Standards and will be seen as State of the Art, and would be considered as part of the evaluation process by Notified Bodies.

No “grandfathering” provisions – Under the MDR, all currently approved devices must be recertified in accordance with the new requirements. Manufacturers with currently approved devices will have three years to demonstrate compliance with the MDR’s new requirements. Exemptions are under negotiation right now.
The MDR timeline

The MDR was officially published on 5 May 2017 and came into force on 25 May 2017. Manufacturers of currently approved medical devices will have a transition time of three years until 26 May 2020 to meet the requirements of the MDR.

It is important to note that, as an EU regulation, the MDR will have the force of law throughout the EU after the date of application. This approach will eliminate country-by-country interpretations of the requirements permitted under current directives, and is also likely to speed up the actual effective date of the MDR’s requirements across the EU.

How you can prepare?

The complex development process for medical devices, combined with the changes, are likely to make the transition a complicated and time consuming process for most device manufacturers.

Because of these complexities, medical device manufacturers are well-advised to stay current on the progress of the MDR through the regulatory approval process, as well as additional changes that may impact them. In addition, since a large number of medical devices are expected to require Notified Body review and approval, delays in the review and approval process by Notified Body should be expected. Manufacturers of currently approved devices are therefore advised to evaluate potential compliance issues and to develop a plan to address them promptly. Advanced preparation and early action will be key to ensuring a smooth transition to the new requirements.

How we can help?

TÜV SÜD is closely following developments related to the MDR, and will regularly provide updated information to our clients through various resources such as webinars, whitepapers, information factsheets etc. These and other resources are designed to help medical device manufacturers stay fully informed about the anticipated changes, and to provide assistance in achieving compliance with the new requirements.

TÜV SÜD is the world’s largest EU Notified Body for all types of medical devices covered by EU directives and regulations. We are also a leading global management certification body for quality management systems, including management systems applicable in the manufacture of medical devices. This unique combination of experience makes TÜV SÜD ideally suited to address the needs of medical device manufacturers seeking to achieve or maintain compliance with medical device requirements in the EU and other major markets around the world.

Why choose TÜV SÜD?

TÜV SÜD offers a complete range of testing, auditing and certification services to manufacturers of medical devices, helping them to manage risks and to protect and promote the health and safety of patients. Our global network of more than 500 dedicated medical health services professionals include scientists and physicians recognised as authorities in their respective fields. These capabilities make TÜV SÜD the preferred single source for worldwide compliance with medical device regulations.

Choose certainty. Add value.

TÜV SÜD is a premium quality, safety and sustainability company that specialises in testing, inspection, auditing and certifications. Represented in over 1000 locations worldwide, we hold accreditations in Europe, the Americas, the Middle East, Asia and Africa. By delivering services to our customers, we add tangible value to businesses, consumers and the environment.

Related services

TÜV SÜD provides the following related services:
- Global approval of medical devices (foreign affairs)
- ISO 9001 – Quality management system certification
- ISO 13485 – Quality management system certification for medical devices
- Medical device market assessment and certification
- Medical device testing
What is a medical device?
A medical device means any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more defined specific medical purposes.

Who is a manufacturer?
The directive defines a manufacturer as a natural or legal person who is responsible for the design, manufacture, packaging and labeling of a medical device with regards to marketing in his own name, regardless of whether these actions are performed by the person himself or a third party deputizing for this person. Manufacturers outside of the EU require, in addition, a representative within the EU.

Classification of medical devices by their risk potential
Annex VIII of the directive stipulates the classification of the devices according to its risk potential, in classes I (low), IIa, IIb and III (high). Depending on the classification of the product, the conformity assessment procedures apply. The directive includes 22 classification rules covering duration of use, level of invasiveness, location of use and energy supply.